<DOC>
	<DOCNO>NCT02042573</DOCNO>
	<brief_summary>Low frequency rTMS ( repetitive Transcranial Magnetic Stimulation ) treatment patient depression , responsible decrease expression C-FOS DUSP1 gene peripheral blood leukocyte . The decrease C-FOS expression could explain inhibit effect low-frequency rTMS ( contrast , high-frequency rTMS cause activation cerebral cortex ) [ Rossi , 2009 ] . This genetic effect could correlate antidepressant effect [ Hausmann , 2000 ] . According hypothesis , genetic effect relate medical antidepressant treatment deserves study could observe : - either decrease expression C-FOS DUSP1 gene relate antidepressant effect medical antidepressant treatment , - increase expression C-FOS DUSP1 gene related cerebral activation due medical antidepressant treatment . In summary , wish determine validity hypothesis compare genetic effect rTMS medical antidepressant know : - genetic effect specific rTMS common rTMS medical antidepressant - effect correlate clinical improvement induce rTMS medical antidepressant - early modification C-FOS DUSP1 gene may predictor therapeutic response rTMS antidepressant ( early decrease gene expression ) - absence decrease increase C-FOS /or DUSP1 expression predictor therapeutic resistance rTMS and/or medical antidepressant .</brief_summary>
	<brief_title>Preliminary Study Investigate Effect rTMS SSRI Antidepressants Leukocyte Expression C-FOS DUSP1 Genes Patients Treated Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Depressive patient treat rTMS SSRI : provide write informed consent cover national health insurance scheme suffer characterize depression ( DSMIV criterion ) consider severe ( Hamilton17 item scale ≥ 19 ) age 1865 year , male female present least one fail treatment medical antidepressant prescribe effective dosage duration least 6 week . Controls : Patients provide write informed consent cover national health insurance scheme age 18 65 year either male female Depressive patient destine benefit treatment rTMS SSRI : Type I II bipolar disorder Depression characteristic psychosis Schizophrenia Abuse alcohol and/or illegal psychoactive substance . Dependence alcohol and/or illegal psychoactive substance . Patients unable provide consent protocol mental disorder include study : patient enforce psychiatric care ( SDT , SDRE ) ward court . Contraindication rTMS ; personal history convulsion , pacemaker , neurosurgical clip , carotid aortic clip , cardiac valve , audition prosthesis , ventricular derivation valve , suture metallic thread staple , foreign body eye , shrapnel , protheses cephalic ferromagnetic implant , metal worker . Contraindication cerebral MRI Resistance escitalopram sertraline ( prescription escitalopram 20 mg/d sertraline 50 mg/d least 6 week last episode ) Contraindication escitalopram : Hypersensitivity escitalopram one excipients . nonselective irreversible monoamine oxidase ( IMAO ) inhibitor , risk serotoninergic syndrome agitation , tremble , hyperthermia . reversible MAOA inhibitor ( e.g . : moclobemide ) nonselective reversible MAO inhibitor ( linezolid ) , give risk serotoninergic syndrome sertraline : Hypersensitivity one component , Hypersensitivity soja , Hypersensitivity arachides , Treatment IMAO Current pregnancy breastfeeding : assay urinary betaHCG do inclusion protocol woman childbearing age . Contraindication escitalopram : Hypersensitivity escitalopram one excipients . Noselective , irreversible monoamine oxidase ( IMAO ) , risk serotoninergic syndrome agitation , tremble hyperthermia . Reversible MAOA inhibitor ( e.g . : moclobemide ) nonselective reversible MAO inhibitor ( linezolid ) , risk serotoninergic syndrome . Patients present acquire congenital prolong QT interval patient treatment know prolong suspected prolong QT interval ( list treatment azcert.org ) . Contraindication sertraline : Hypersensitivity one component , Hypersensitivity soja , Hypersensitivity arachides , Treatment IMAO . Patients treat pimozide . Controls : Any current psychiatric disease history psychiatric disease ( define DSMIVTR criterion ) Current addiction ( except occasional smoking ) history addiction ( define DSMIVTR criterion ) Any progressive somatic disease ( cardiac , hepatic , renal , pulmonary… ) Any pharmacological treatment exception combine oral contraceptive pill Current pregnancy breastfeeding : urinary betaHCG assay inclusion protocol woman childbearing age . Personnel employ psychiatry addictology department Dijon CHU</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>